Sign In
Buy LIFE
$16.89
-0.375 (-2.17%)
At Close: Jun 03, 2026
DiagnaMed Announces LIFE Offering of up to $650,000
06:10pm, Wednesday, 15'th May 2024
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI,
aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference
07:00am, Wednesday, 15'th May 2024
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
08:00am, Tuesday, 14'th May 2024
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod.
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
04:00pm, Thursday, 02'nd May 2024
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivale
aTyr Pharma to Participate in April Investor Conferences
08:00am, Monday, 01'st Apr 2024
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
02:19pm, Tuesday, 26'th Mar 2024
When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we're done here, right?
aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript
11:37pm, Thursday, 14'th Mar 2024
aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
04:00pm, Thursday, 14'th Mar 2024
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP),
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
08:00am, Wednesday, 28'th Feb 2024
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
08:00am, Wednesday, 21'st Feb 2024
Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT™ study inve
The 3 Best Penny Stocks to Buy in February 2024
07:49am, Thursday, 15'th Feb 2024
Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of co
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
08:00am, Thursday, 18'th Jan 2024
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).
Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models. Efzofitimod demonstrated immune regulatory function improving disease outcomes
aTyr Pharma to Present at November Investor Conferences
08:00am, Wednesday, 01'st Nov 2023
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023.
